Lomefloxacin (Contra) is a broad-spectrum antibiotic used to provide anti-infective support, generally applied in situations involving acute bacterial infections that present with pronounced symptoms. Its use is centered on the elimination of the causative bacteria to support symptomatic relief and may assist in managing the progression of the infection.

Lomefloxacin is indicated for the treatment of lower respiratory tract infections, urinary tract infections (UTIs), and for pre-operative prophylaxis of UTIs prior to certain surgical procedures. This helps maintain functional stability during periods of heightened symptomatic burden.

---

Main Uses and Therapeutic Benefit

Lomefloxacin is used across therapeutic domains involving bacterial infection, including ocular surface infections (like bacterial conjunctivitis and keratitis), systemic urinary tract infections, and acute exacerbations of chronic bronchitis. It is applied in clinical settings that involve acute or unstable symptom patterns, such as intense redness and tearing in the eye, or painful urination and worsening cough in respiratory disease. The medication supports patients during episodes of heightened symptoms by addressing the infection, which contributes to easing the overall symptom burden.

---

“The primary goal is to provide supportive relief during acute symptomatic episodes, assisting with the discomfort linked to bacterial proliferation.”

---

Quick Fact: Relief for Pronounced Symptoms
Lomefloxacin is commonly used to help manage symptoms related to inflammatory or irritative states in the eyes and urinary tract. It provides supportive relief when acute manifestations interfere with functional stability.

Who Can and Cannot Use Contra?

The use of Lomefloxacin (Contra) is defined by strict regulatory eligibility criteria, primarily based on contraindications related to hypersensitivity, age, and pre-existing medical conditions.

Absolute Contraindications

Lomefloxacin is absolutely contraindicated in patients with a known history of hypersensitivity to the drug itself or to any other quinolone/fluoroquinolone antibiotic. The systemic form is also contraindicated in pediatric patients (under 18 years of age), as safety and effectiveness have not been established for this age group.

Condition-Based Restrictions

Eligibility is restricted for patients with certain comorbidities. The medicine must not be used in individuals with a history of tendon disorders associated with prior quinolone use, known or suspected Myasthenia Gravis, or conditions that may lead to prolongation of the QT interval. Patients with severe renal impairment require special consideration.

High-Risk and Reproductive Status

Use requires special caution in older adults due to an increased risk of severe tendon disorders. In pregnancy (FDA Category C), the drug is generally reserved for cases where the potential benefit justifies the risk. For breastfeeding mothers, official guidance recommends discontinuing nursing or discontinuing the drug.

Interactions with other medicines and products

The official regulatory profile for Lomefloxacin (Contra) tablets is defined by specific interactions affecting systemic exposure and pharmacodynamic risk. Absorption interference is the primary pharmacokinetic concern, necessitating strict administration rules.

---

Official Interaction Statements

Category	Official Interaction Data or Statement
Exposure-Modifying Substances	Products containing Multivalent Cations (e.g., Aluminum, Iron, Magnesium, Zinc in antacids or supplements) cause a significant decrease in Lomefloxacin systemic absorption (reduced AUC/Cmax) due to chelate formation.
Timing / Separation Rules	The reduction in absorption from multivalent cations requires a time separation. Lomefloxacin must be administered at least 2 hours before the cation-containing product.
Metabolic Interactions	Lomefloxacin exhibits a lack of significant metabolism, meaning no competitive drug interactions with other medicines relying on common metabolic enzyme systems are documented.
Pharmacodynamic Risk	Co-administration with other Drugs that Prolong the QT Interval is associated with an increased risk or severity of QTc prolongation.

---

Population and Food Notes

The absorption of Lomefloxacin tablets is affected by food, which results in a delayed rate and reduced extent of absorption. Additionally, official pharmacokinetic summaries state that Lomefloxacin dosage regimens do not require alteration for patients with hepatic impairment (liver disease), indicating non-interaction in this population.

This structure establishes the critical non-metabolic nature of Lomefloxacin's interaction pattern, primarily focusing on the necessary constraints to ensure proper systemic uptake.

Lomefloxacin's mechanism of action is rooted in the highly selective inhibition of two essential bacterial enzymes: DNA gyrase and Topoisomerase IV. The drug gains entry into the prokaryotic cell, seeking to interfere with these Type II Topoisomerases, which are vital for managing the structural integrity of the bacterial chromosome during replication and segregation. Lomefloxacin functions as an inhibitor by binding to and stabilizing the temporary complex formed between the enzyme and the newly cleaved DNA, thereby preventing the critical resealing step.

This molecular interference transforms the enzymes into a source of widespread double-strand DNA breaks across the bacterial genome. The accumulation of these unrepaired breaks immediately halts the processes of DNA replication and transcription within the cell. The subsequent cascade of genomic damage overwhelms the bacterium's repair systems, leading swiftly to irreversible cell death. The intended action is constrained by biological factors like QRDR mutations or efflux pumps, which reduce drug affinity or intracellular concentration.

How to Use Contra: Official Administration Guidelines

Lomefloxacin (Contra) is administered via two distinct official pathways, which dictate the dosing regimen and procedural steps. The medicine is used either through the Oral route (as film-coated tablets for systemic treatment) or the Topical route (as an ophthalmic solution for local ocular use).

---

Standard Dosing and Frequency

Feature	Official Instruction Summary
Oral Dose (Systemic)	400 mg (milligrams) once daily for all therapeutic indications. A single 400 mg dose is used for pre-operative prophylaxis.
Topical Dose (Ophthalmic)	1 drop into the affected eye(s) 2 to 3 times per day. Intensive treatment may involve administration up to hourly for the initial 6–10 hours of therapy.
Duration of Use	Oral use ranges from a single prophylactic dose to a maximum course of 14 days, depending on the specific condition. Topical use is typically fixed around a 7 to 9-day course.

---

Procedural and Population Constraints

Oral tablets may be taken without regard to meals and must be swallowed whole with adequate fluid. A key procedural constraint mandates that the oral tablet should be administered at least 4 hours before or 8 hours after ingesting compounds containing minerals, such as iron, zinc, or antacids that contain magnesium or aluminum.

Population-specific adjustments are required for patients with documented renal impairment. Specifically, for those with a Creatinine Clearance of 10 - 40 mL/min, the initial 400 mg dose is followed by a reduced maintenance dose of 200 mg once daily. No dose adjustment is specified for individuals with hepatic impairment, provided their renal function is adequate.

Research Evidence / Overview of Studies for Contra

---

Evidence for Use in Acute Ocular Infections (Eye Drops)

Research examining the Lomefloxacin ophthalmic solution primarily involved short-term Randomized Controlled Trials (RCTs). These studies were designed to evaluate the regimen against other established regimens or placebo for external ocular infections like bacterial conjunctivitis. Studies monitored measured changes in visible signs (redness, tearing) and the bacteriological status of the eye surface. Findings describe patterns observed over periods typically lasting up to two weeks. However, limited information is available for long-term outcomes regarding the durability of these patterns or the incidence of recurrence.

---

Evidence for Use in Urinary Tract Infections (Systemic Tablets)

Lomefloxacin research includes RCTs and meta-analyses that explored its use in both uncomplicated and complicated UTIs. Trials monitored outcomes like measured changes in pain or urination frequency, and research examined the clearance of specific bacteria. A separate research area involved pre-operative prophylaxis, where studies monitored patterns related to the incidence of post-surgical UTIs. The clinical applicability of older evidence must be considered alongside the growing prevalence of antibiotic resistance.

---

Evidence for Use in Lower Respiratory Tract Infections (Systemic Tablets)

RCTs also evaluated the systemic tablets for conditions involving heightened symptoms, specifically acute exacerbations of chronic bronchitis (AECB). Studies assessed outcomes related to clinical status and bacteriological status from respiratory samples, with findings describing measured changes in symptoms and patterns of bacterial status. Comparative evidence against current first-line antibiotics is lacking, and results apply most confidently to the populations studied in the controlled trials.

---

Research Gaps and Areas of Uncertainty

The majority of evidence is derived from short-term clinical trials. Long-term effects are not fully established, and there is limited information regarding the durability of observed patterns. While research examined pediatric patients (for eye drops) and older adults, data remains insufficient for individuals with significant co-existing chronic medical conditions. The research landscape indicates several areas where certainty remains low due to the age of pivotal trials and the context of evolving antimicrobial resistance.

Key Studies & References Maxaquin (lomefloxacin hydrochloride tablet) Label

Common questions about Contra (FAQ)

---

Q: How does Contra's function differ from standard over-the-counter pain relievers?

Contra is classified by regulatory authorities as a Fluoroquinolone antibiotic. Its purpose is to act as a bactericidal agent, meaning it kills bacteria to treat an infection.

This differs from standard over-the-counter pain relievers, which are typically analgesics designed only to block pain and reduce inflammation.

---

Q: Are there warnings about Contra affecting liver or kidney function?

Official prescribing information indicates the kidney plays a role in eliminating the medicine, requiring dosage adjustments for individuals with pre-existing renal impairment (kidney function issues).

However, no specific adjustment is noted for those with hepatic (liver) impairment, provided their kidney function is adequate.

---

Q: What does official guidance say about managing a missed dose of Contra?

Official patient guidance generally describes the recommended procedure if a dose is missed: taking it as soon as it is remembered. If the next scheduled time is near, the guidance recommends skipping the missed dose and resuming the regular schedule.

Regulatory information indicates that a double dose should not be taken to compensate for a missed dose.

---

Q: Can I take Contra with my usual vitamins or supplements?

Official interaction statements warn that supplements containing multivalent cations, such as iron, zinc, or magnesium (often found in multivitamins or antacids), can significantly interfere with the absorption of Lomefloxacin.

A required time separation is noted in the instructions, mandating that these products be taken at least two hours after Contra to manage the risk of reduced systemic exposure.

---

Q: Does the official guidance mention any known interactions between Contra and alcohol or caffeine?

The official regulatory information for Lomefloxacin does not list a specific interaction with either alcohol or caffeine.

However, the medicine is known to cause potential Central Nervous System (CNS) side effects like dizziness and tremor.

---

Q: Does Contra interact with hormonal birth control methods?

Regulatory reviews of the Fluoroquinolone class suggest that Lomefloxacin, unlike some other types of antibiotics, is not expected to significantly reduce the effectiveness of hormonal birth control.

Guidance indicates that patients must consult the prescribing information for specific details related to contraception.

---

Q: What is the official recommendation regarding discontinuing the use of Contra?

Official guidance emphasizes the importance of completing the full prescribed course of treatment for adequate infection clearance. Regulatory text describes a procedure for immediate discontinuation if signs of a serious side effect occur, such as tendon pain or symptoms of nerve damage.

In these circumstances, the official information states that use must be stopped and professional medical attention sought.

---

Q: Is Contra considered a newer drug or has it been available for a long time?

Lomefloxacin is formally classified as a second-generation fluoroquinolone. It was first patented in the early 1980s and was initially approved for medical use in the United States in 1989.

This classification indicates it is a mature drug that has been available for a significant period.

---

Q: Where can patients access the summary of clinical trial information for Contra?

The summary of official regulatory documents, including the full Prescribing Information and overviews of clinical trial data, is made publicly available by government bodies.

These can be accessed through national drug databases such as the FDA Drugs@FDA database or the NIH’s ClinicalTrials.gov.

---

Q: Is there a generic version of the active ingredient in Contra available?

Yes, the active ingredient in Contra, known as Lomefloxacin hydrochloride, is widely available as a generic medicine.

These generic equivalents are manufactured by various companies and are typically listed in national drug directories.

---

Q: Has Contra been specifically studied for use in pediatric populations?

The systemic oral tablet form of Lomefloxacin is contraindicated in pediatric patients (under 18 years of age) due to regulatory concerns over established safety and effectiveness.

However, the ophthalmic solution (eye drop) form is approved for local ocular use in children.

---

Q: Why is there extensive warning information listed in the Contra package leaflet?

The extensive warnings are required because Lomefloxacin is part of the Fluoroquinolone antibiotic class. This class carries a regulatory-mandated warning due to the risk of serious, potentially disabling, and long-lasting adverse reactions primarily involving the tendons and nervous system.

---

Q: Is Contra classified as a controlled substance?

No, official government regulatory bodies, such as the DEA and Health Canada, do not classify Contra (Lomefloxacin) as a controlled substance.

It is categorized purely as an antibiotic.

---

Q: Does Contra carry any official warnings regarding the risk of dependence or addiction?

No, the official regulatory information for Lomefloxacin, including the Prescribing Information and patient guides, does not contain any warnings regarding the risk of dependence or addiction.

---

Q: What is the function of the inactive ingredients listed in Contra?

Inactive ingredients do not have a therapeutic effect but are necessary for the product. They serve practical functions such as stabilizing the medicine over time, acting as fillers to form the tablet shape, or providing the film-coating for protection and easier swallowing.

---

Q: What is the necessity for Contra to be obtained via prescription?

Lomefloxacin is restricted to prescription use because it is an antibiotic. This control mechanism is in place to support the proper use of the medicine for specific bacterial infections, manage potential side effects, and contribute to efforts to limit the development of antibiotic resistance.

---

Q: Will taking Contra potentially affect a person's ability to drive or operate machinery?

Official guidance states that Lomefloxacin can cause Central Nervous System side effects such as dizziness, lightheadedness, or tremor. Because these effects may impair judgment, the official information advises against operating machinery or driving until the individual is aware of the medicine's effect on their abilities.

---

Q: Has a link been observed between Contra use and changes in body weight (gain or loss)?

A review of official regulatory documents, including the full adverse reaction profile, indicates that the medicine does not list changes in body weight (gain or loss) as a reported adverse reaction for Lomefloxacin.

---

Q: What does the medical jargon term '[specific jargon term]' mean in the Contra documentation?

When specific medical jargon is used in official documentation, it refers to defined clinical concepts. For example, Peripheral Neuropathy, a serious warning, describes nerve damage outside the brain and spinal cord, resulting in symptoms like pain, burning, tingling, numbness, or weakness.

---

Q: Does Contra contain any ingredients that are derived from animals?

The active ingredient is a synthetic chemical. However, the presence of animal-derived components, such as gelatin or specific forms of lactose, is dependent on the inactive ingredients chosen by the manufacturer. This information would be detailed in the product's full ingredient description.

---

Q: What is the descriptive difference between the brand name Contra and its generic equivalent?

Regulatory standards require the generic equivalent to contain the identical active ingredient (Lomefloxacin) and be therapeutically equivalent to the brand name product in strength, safety, and efficacy.

Any differences are generally limited to the inactive ingredients, the product's appearance, and its packaging.

---

Q: Is Contra a drug that requires blood monitoring during treatment?

Lomefloxacin does not routinely require blood monitoring for all patients. However, as it belongs to the Fluoroquinolone class, official guidance suggests that increased vigilance regarding blood glucose levels may be warranted for patients with diabetes or other high-risk factors during treatment.

---

Q: What is the expected time frame for noticing the full therapeutic effects of Contra, according to clinical research?

The full therapeutic effect is typically measured based on clinical and microbiological outcomes over the prescribed course.

Clinical trials studied these outcomes over a treatment period typically lasting 7 to 14 days, which reflects the time required to achieve successful treatment.

How to Store and Dispose of Lomefloxacin (Contra)

Storage Conditions

Lomefloxacin must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The product must be protected from light, excessive heat, and moisture. Do not allow the ophthalmic solution to freeze.

Store the medicine in its original container, ensuring the ophthalmic solution bottle is tightly closed when not in use. It is required to keep Lomefloxacin out of the sight and reach of children.

Stability and Disposal

Use the product before the stated expiry date. The ophthalmic solution must be discarded one month after opening.

Do not throw away unused or expired medicine via wastewater or household waste. Disposal must follow the instructions of a healthcare professional or an official local take-back program.